Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
107.48(c) 106.48(c) 107.77(c) 108.08(c) 107.73(c) Last
7 398 901 6 102 705 7 444 253 5 821 818 13 488 909 Volume
+0.75% -0.93% +1.21% +0.29% -0.32% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 56 247 M - -
Net income 2021 12 652 M - -
Net Debt 2021 66 393 M - -
P/E ratio 2021 14,6x
Yield 2021 4,76%
Sales 2022 59 589 M - -
Net income 2022 15 370 M - -
Net Debt 2022 53 426 M - -
P/E ratio 2022 11,9x
Yield 2022 5,13%
Capitalization 190 B 190 B -
EV / Sales 2021 4,57x
EV / Sales 2022 4,09x
Nbr of Employees 48 000
Free-Float 98,0%
More Financials
Company
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human... 
Sector
Pharmaceuticals
Calendar
10/14Ex-dividend day for
More about the company
Ratings of AbbVie Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ABBVIE INC.
09/16ABBVIE : Files Regulatory Applications in US and Europe for Upadacitinib to Trea..
MT
09/16ABBVIE : Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ..
PR
09/16AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib for th..
CI
09/16AbbVie Submits Regulatory Applications for Treatment of Ulcerative Colitis
DJ
09/15China's biotech sector comes of age with big licensing deals, global ambition..
RE
09/14ABBVIE : and REGENXBIO Announce Eye Care Collaboration
AQ
09/14REGENXBIO : RBC Lifts Price Target on REGENXBIO to $55 From $50, Sees Eye Care D..
MT
09/13Health Care Stocks Still Adding to Afternoon Slide
MT
09/13Health Care Stocks Slipping Monday Afternoon
MT
09/13REGENXBIO : Partners with AbbVie to Commercialize RGX-314 for Retinal Eye Diseas..
MT
09/13ABBVIE : Declares Quarterly Dividend
AQ
09/13ABBVIE : to Highlight Its Leadership in Movement Disorders at the International ..
AQ
09/13APPLE : Energy, financials help Wall Street rise from bruising week
RE
09/13Wall Street Set for Rebound After Week of Losses
MT
09/13Regenxbio Shares Jump After Collaborating With AbbVie on Eye Therapy
DJ
More news
News in other languages on ABBVIE INC.
09/16AbbVie dépose des demandes d'homologation aux États-Unis et en Europe pour l'..
09/13Les actions du secteur de la santé continuent de s'enfoncer dans l'après-midi
09/13Les actions du secteur de la santé en baisse lundi après-midi
09/13REGENXBIO s'associe à AbbVie pour commercialiser le RGX-314 contre les maladi..
09/13ABBVIE : partenariat avec Regenxbio
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 107,73 $
Average target price 125,48 $
Spread / Average Target 16,5%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman-Management Board & President
Robert A. Michael Chief Financial Officer & Executive Vice President
Thomas J. Hudson Chief Scientific Officer, Senior VP-R&D
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.0.54%190 378
JOHNSON & JOHNSON4.68%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.20.81%249 329
NOVO NORDISK A/S51.34%233 887
ELI LILLY AND COMPANY36.28%209 456